Summary
The provided content does not contain an AI-generated labeling claim to evaluate against the FDA-approved prescribing information. Therefore, alignment to on-label statements cannot be assessed, and the response does not support any specific regulatory labeling conformity claim.
Category Scores
Accurate Statements
Unsupported Statements
Supported: **no** / Contradicted: **no** / Mentioned: **no** (because the user’s specific claim was not provided).
No evaluable AI claim or label-conformity statement was provided to validate this determination against the FDA-approved prescribing information.
Contradictions
Important Omissions
A specific, checkable AI claim about Promethazine DM (e.g., indication, dosing, contraindications, warning content, interactions, or safety) that can be compared line-by-line to the FDA label.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
No specific dosing, safety, or therapeutic instruction was provided by the AI content to affect patient management; the issue is evaluation incompleteness rather than an unsafe label assertion.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Assessable
Primary Issue
No specific AI-generated claim text was provided for evaluation against the supplied FDA label excerpts.
Suggested Improvement
Provide the exact AI response statements to be audited (or the specific user claim), and specify the exact product/label portion relevant to each claim (e.g., Promethazine DM oral solution 15 mg/5 mL + 6.25 mg/5 mL).